These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 33374715)
21. Scandium-44 Radiolabeled Peptide and Peptidomimetic Conjugates Targeting Neuropilin-1 Co-Receptor as Potential Tools for Cancer Diagnosis and Anti-Angiogenic Therapy. Masłowska K; Redkiewicz P; Halik PK; Witkowska E; Tymecka D; Walczak R; Choiński J; Misicka A; Gniazdowska E Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831099 [TBL] [Abstract][Full Text] [Related]
22. Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex. Starzec A; Ladam P; Vassy R; Badache S; Bouchemal N; Navaza A; du Penhoat CH; Perret GY Peptides; 2007 Dec; 28(12):2397-402. PubMed ID: 17983687 [TBL] [Abstract][Full Text] [Related]
23. Mechanism of selective VEGF-A binding by neuropilin-1 reveals a basis for specific ligand inhibition. Parker MW; Xu P; Guo HF; Vander Kooi CW PLoS One; 2012; 7(11):e49177. PubMed ID: 23145112 [TBL] [Abstract][Full Text] [Related]
24. Neuropilin-1 expression promotes invasiveness of melanoma cells through vascular endothelial growth factor receptor-2-dependent and -independent mechanisms. Ruffini F; D'Atri S; Lacal PM Int J Oncol; 2013 Jul; 43(1):297-306. PubMed ID: 23685409 [TBL] [Abstract][Full Text] [Related]
25. Upregulation of neuropilin-1 by basic fibroblast growth factor enhances vascular smooth muscle cell migration in response to VEGF. Liu W; Parikh AA; Stoeltzing O; Fan F; McCarty MF; Wey J; Hicklin DJ; Ellis LM Cytokine; 2005 Dec; 32(5):206-12. PubMed ID: 16289960 [TBL] [Abstract][Full Text] [Related]
26. A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. Tirand L; Frochot C; Vanderesse R; Thomas N; Trinquet E; Pinel S; Viriot ML; Guillemin F; Barberi-Heyob M J Control Release; 2006 Mar; 111(1-2):153-64. PubMed ID: 16423422 [TBL] [Abstract][Full Text] [Related]
28. VEGF but not PlGF disturbs the barrier of retinal endothelial cells. Deissler HL; Deissler H; Lang GK; Lang GE Exp Eye Res; 2013 Oct; 115():162-71. PubMed ID: 23891860 [TBL] [Abstract][Full Text] [Related]
29. HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165. Lambert S; Bouttier M; Vassy R; Seigneuret M; Petrow-Sadowski C; Janvier S; Heveker N; Ruscetti FW; Perret G; Jones KS; Pique C Blood; 2009 May; 113(21):5176-85. PubMed ID: 19270265 [TBL] [Abstract][Full Text] [Related]
30. New peptide MY1340 revert the inhibition effect of VEGF on dendritic cells differentiation and maturation via blocking VEGF-NRP-1 axis and inhibit tumor growth in vivo. Mo Z; Yu F; Han S; Yang S; Wu L; Li P; Jiao S Int Immunopharmacol; 2018 Jul; 60():132-140. PubMed ID: 29730556 [TBL] [Abstract][Full Text] [Related]
31. Distinct heparin binding sites on VEGF165 and its receptors revealed by their interaction with a non sulfated glycoaminoglycan (NaPaC). Di Benedetto M; Starzec A; Vassy R; Perret GY; Crépin M Biochim Biophys Acta; 2008 Apr; 1780(4):723-32. PubMed ID: 18325345 [TBL] [Abstract][Full Text] [Related]
32. Relative effects of VEGF-A and VEGF-C on endothelial cell proliferation, migration and PAF synthesis: Role of neuropilin-1. Bernatchez PN; Rollin S; Soker S; Sirois MG J Cell Biochem; 2002; 85(3):629-39. PubMed ID: 11968003 [TBL] [Abstract][Full Text] [Related]